Because new biologic treatments for asthma can be expensive and cause side effects, we need to come up with a protocol that lists specific factors, such as how well patients follow their treatment plan, so that only the patients who will benefit from biologic treatment are given it. Along with many other things, this has been one of the RASP-UK consortium's goals for the past 3 years. At the recent RASP-UK Annual Consortium Meeting, people heard about the published results of a part of the project that looked at what happens when people with severe asthma don't follow their treatment plans [1]. Poor adherence is common in difficult-to-control asthma, making the identification of patients with difficult-to-control asthma who respond to inhaled corticosteroids from refractory asthma clinically challenging.
Suppressing fractional exhaled nitric oxide (FeNO) with directly watched corticosteroid therapy over 7 days has been suggested as a way to find patients who aren't following their corticosteroid treatment. Using remote monitoring technologies, the RASP team looked into whether FeNO suppression testing could be done and how useful it would be in regular clinical care in its UK severe asthma centres.
To provide FeNO suppression testing, web-based recording and built-in remote tracking technology have been created. As part of our ongoing research, we looked at the clinical worth of testing and how well it could show how steroid drugs work and provide clinical benefit.
The study successfully showed that monitoring FeNO suppression from afar is a good way to find people with difficult-to-control asthma who aren't taking their inhaled corticosteroids as prescribed. This includes a large group of patients who are likely to benefit greatly from better inhaled asthma therapy.
The findings have already received an enthusiastic reception in the literature [2]. A recent review praises the progress made in creating a useful, standardised method for checking adherence and inflammation control that can tell the difference between patients who need a biologic medication and those whose symptoms aren't getting better because they aren't following standard inhaled therapy. It's clear that RASP-UK is a well-run and successful consortium that will soon be delivering exciting and clinically useful results.
References
It was encouraging to see so many partners at the 2017 General Assembly meeting last December
Investigator-Initiated Clinical Trials (IITs) are clinical studies led by academic researchers or clinicians
Since 2013 we have been sharing our understanding on key issues with friends and clients via our Insider’s Insights.
The UK's world-class human challenge study gives us new information about SARS-CoV-2 cases that were mild in 36 healthy.
Every year, a huge amount of scientific data is released. It's out there, but how do you find it?
Finding the best vehicle in which to publish your research findings is a perennial challenge.
Investigator sites are very important to clinical studies because they make sure that new drugs are safe and work well.
The proceedings of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI)
Welcome to the seventh issue of the Refractory Asthma Stratification Programme (RASP-UK) newsletter
ive years ago I was lucky enough to be involved in a project that resulted in publications
Get our latest news and publications
Sign up to our news letterResources
Social
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
